InteractiveFly: GeneBrief

Chorion factor 2: Biological Overview | References

Gene name - Chorion factor 2

Synonyms -

Cytological map position - 25B1-25B1

Function - transcription factor

Keywords - Oogenesis, myogenesis

Symbol - Cf2

FlyBase ID: FBgn0000286

Genetic map position - 2L: 4,877,289..4,883,113 [-]

Classification - C2H2 zinc finger

Cellular location - nuclear

NCBI link: EntrezGene

Cf2 orthologs: Biolitmine
Recent literature
Arredondo, J. J., Vivar, J., Laine-Menendez, S., Martinez-Morentin, L. and Cervera, M. (2017). CF2 transcription factor is involved in the regulation of Mef2 RNA levels, nuclei number and muscle fiber size. PLoS One 12(6): e0179194. PubMed ID: 28617826
CF2 and Mef2 influence a variety of developmental muscle processes at distinct stages of development. Nevertheless, the exact nature of the CF2-Mef2 relationship and its effects on muscle building remain yet to be resolved. This study explored the regulatory role of CF2 in the Drosophila embryo muscle formation. To address this question and not having proper null CF2 mutants, loss or gain of function strategies were employed to study the contribution of CF2 to Mef2 transcription regulation and to muscle formation. The data point to CF2 as a factor involved in the regulation of muscle final size and/or the number of nuclei present in each muscle. This function is independent of its role as a Mef2 collaborative factor in the transcriptional regulation of muscle-structural genes. Although Mef2 expression patterns do not change, reductions or increases in parallel in CF2 and Mef2 transcript abundance were observed in interfered and overexpressed CF2 embryos. Since CF2 expression variations yield altered Mef2 expression levels but with correct spatio-temporal Mef2 expression patterns, it can be concluded that only the mechanism controlling expression levels is de-regulated. It is proposed that CF2 regulates Mef2 expression through a Feedforward Loop circuit.

The process of myogenesis requires the coordinated activation of many structural genes whose products are required for myofibril assembly, function, and regulation. Although numerous reports have documented the importance of the myogenic regulator myocyte enhancer factor 2 (MEF2) in muscle differentiation, the interaction of MEF2 with cofactors is critical to the realization of muscle fate. This study identified a genomic region required for full MEF2-mediated activation of actin gene expression in Drosophila, and the zinc finger transcriptional regulator Chorion factor 2 (CF2) was identified as a factor functioning alongside MEF2 via this region. Furthermore, although both MEF2 and CF2 can individually activate actin gene expression, these two factors collaborate in regulating the Actin57B target gene in vitro and in vivo. More globally, MEF2 and CF2 synergistically activate the enhancers of a number of muscle-specific genes, and loss of CF2 function in vivo results in reductions in the levels of several muscle structural gene transcripts. These findings validate a general importance of CF2 alongside MEF2 as a critical regulator of the myogenic program, identify a new regulator functioning with MEF2 to control cell fate, and provide insight into the network of regulatory events that shape the developing musculature (Tanaka, 2008).

A major function of the mesodermal germ layer during embryogenesis is the generation of myogenic tissue and the subdivision of cells into skeletal, cardiac, and visceral muscle precursors. This process has been broadly conserved during evolution. Specification of the three major muscle lineages is conserved from Drosophila to mammals, and conserved structural genes are activated in each lineage to provide power for locomotion, circulation, and digestion (Tanaka, 2008).

The transcription factors that mediate muscle cell differentiation are also broadly conserved. Foremost among these proteins are members of the myocyte enhancer factor 2 (MEF2) family of transcriptional regulators. MEF2 proteins dimerize and bind to DNA via conserved MADS and MEF2 protein domains, and MEF2 proteins recognize an AT-rich sequence, which is found in the promoters and enhancers of numerous muscle-specific genes. MEF2-encoding genes are found in all animal genomes, from single-gene copies in Caenorhabditis elegans (named CeMef2) and Drosophila melanogaster (named Mef2), to four genes in mammals (named mef2a to -d) (Tanaka, 2008).

Consistent with the pervasiveness of MEF2 sites in muscle-specific genes and the conservation of this gene family during evolution, mutational studies in several animal models have established important roles for MEF2 factors in muscle differentiation. In Drosophila, inactivation of the single Mef2 gene resulted in a complete failure of differentiation for all muscle lineages. In mice, inactivation of mef2c resulted in a failure of normal cardiac and visceral muscle development. Furthermore, inactivation of murine mef2a caused cardiac failure shortly after birth. Also, expression of dominant-negative isoforms of MEF2 predicted to inhibit all MEF2 function resulted in the inhibition of skeletal myogenesis in mammalian cells in vitro and in interference in cardiac development in vivo. Finally, a point mutation in the human gene encoding MEF2A is associated with susceptibility to cardiac disease. These studies present a strong argument for the importance of MEF2 proteins in muscle development and disease (Tanaka, 2008).

Despite the critical requirement of MEF2 for muscle differentiation, MEF2 proteins are not themselves capable of activating the myogenic program in naive cells in tissue culture. Similarly in Drosophila, ectopic expression of Mef2 in the ectoderm caused the activation of some muscle-specific markers, and yet failed to induce myogenesis at high levels. These findings suggested that MEF2 must act with specific cofactors in order to control myogenesis. Much progress has subsequently been made in defining both positive and negative cofactors for MEF2, in a variety of muscle tissues. MEF2 collaborates positively with skeletal muscle-specific members of the basic helix-loop-helix family of transcriptional regulators, including MyoD and myogenin, to control skeletal myogenesis. In addition, the SAP domain proteins Myocardin and MASTR also stimulate the transcriptional activity of MEF2 in cardiac and skeletal muscle tissue, respectively. MEF2 proteins also interact with ubiquitous factors, such as the p300 coactivator and members of the histone deacetylase family of transcriptional repressors (Tanaka, 2008).

In Drosophila, there is relatively little direct data concerning the identification of cofactors that might collaborate with MEF2 to control myogenesis. Nevertheless, a number of enhancers for muscle-specific genes have been described, many of which contain MEF2 binding sites that are critical for full gene activation. Among these, the promoter has been described for the Act57B actin gene in Drosophila (Kelly, 2002). Act57B is the predominant embryonic muscle actin, being expressed at high levels in all of the major muscle lineages and also being one of the earliest markers of muscle differentiation in the embryo. Activation of Act57B expression in all embryonic muscle lineages is controlled by a proximal 595-bp promoter element. Within this region, full transcriptional activation required the integrity of a single MEF2 binding site at position -209 relative to the transcriptional start site, validating the importance of MEF2 as a direct regulator of myogenesis in this system. This finding was also supported by the study of Sandmann (2006), who showed, using microarray analysis, that Act57B expression was strongly downregulated in Mef2 mutants. Furthermore, the Sandmann study utilized chromatin immunoprecipitation-microarray analyses to identify the MEF2 site at position -209 as an in vivo target of MEF2 (Tanaka, 2008).

An ~300-bp region distal to the MEF2 site is critical for full Act57B activation in embryonic muscle tissue, suggesting the existence of a MEF2 cofactor that interacted with this distal sequence. This analysis permitted a directed approach to be carried out to identify and functional characterize a MEF2 collaborating factor in Drosophila. This study delineates sequences within the 300-bp distal region that are required for full gene activation in vivo; a nuclear factor binds to this region with the characteristics identical to that of the C2H2 zinc finger transcriptional regulator chorion factor 2 (CF2) (Hsu, 1992). It is further shown that MEF2 and CF2 can each activate Act57B expression in vitro and in vivo and that these factors function synergistically to maintain high levels of actin expression in the Drosophila embryo. More globally, MEF2 and CF2 synergistically activate other muscle structural genes, and loss of CF2 function results in reductions in the expression levels of several muscle structural genes, including Act57B. These findings describe the first collaborating factor for MEF2 in the Drosophila system and further delineate the network of transcriptional events required for normal muscle development (Tanaka, 2008).

A region of the Act57B promoter from positions -593 to +2 can provide robust levels of muscle-specific expression of a lacZ reporter gene in transgenic animals. Within this fragment, at position -209, is a conserved MEF2 binding site that was critical for full promoter activity. Furthermore, 5' deletion of 315 nucleotides to generate a -278/+2 Act57B-lacZ reduced reporter gene expression. These findings established the importance of the MEF2 binding site for full activation of the Act57B gene (Kelly, 2002). However, since the -278/+2 construct showed reduced reporter activity despite retaining the MEF2 binding site at position -209, the data also indicated that a genomic region separate from the MEF2 site was critical for normal levels of gene expression, which might therefore interact with a cofactor for MEF2 (Tanaka, 2008).

To more precisely delineate regions critical to Act57B expression, a further 5' deletion analysis of the -593/+2 fragment was performed. At least three transgenic lines were assessed for each construct, and representative images are presented. Expression of the full-length construct was first detected at stage 11 of embryogenesis in visceral muscle precursors, and by stage 12 in skeletal muscle and visceral muscle precursors; high levels of reporter gene expression were still observed at stage 16 in all muscle lineages. 5' deletion of ~70 bp to position -521 did not affect the initiation of Act57B expression at stage 11, although reporter gene expression levels were consistently reduced at stage 16. This was apparent by the lesser ease with which individual muscle fibers could be distinguished in stained embryos at higher magnifications. A further 5' deletion of 130 bp to position -390/+2 showed no additional strong reduction in reporter gene expression. In contrast, the smallest -278/+2 Act57B-lacZ showed reduced reporter activity at stage 12, and reporter levels also appeared to be further reduced at stage 16 compared to larger genomic fragments that were tested (Tanaka, 2008).

These studies demonstrated that more than one region of the Act57B upstream promoter is required for normal reporter gene expression in vivo. Although it is difficult to assign relative levels of expression in these immunohistochemical stains, two regions seem most critical to normal expression: the region between positions -593 and -521 is a genomic element required for full gene activation at later stages of development, and a more proximal region from positions -390 to -278 is important for the initiation of Act57B expression at stages 11 and 12, as well as for later sustained Act57B expression. Subsequent studies therefore focused initially upon the identification of factors interacting with this more proximal region (Tanaka, 2008).

In order to determine whether factors existed that were capable of interacting with the Act57B promoter region, electrophoretic mobility shift assays were carried out using as a probe a -390/-245 region of the Act57B gene. When this fragment was mixed with nuclear extracts prepared from 12- to 24-h-old Drosophila embryos, the formation was observed of a slowly migrating complex, which is hypothesized to corresponded to a transcription factor capable of regulating Act57B expression (Tanaka, 2008).

To more precisely locate the region of the DNA probe with which the nuclear factor was interacting, binding reactions were compated with sets of double-stranded oligonucleotides spanning the entire probe sequence. It was found that, whereas most of the oligonucleotide competitors failed to reduce the intensity of the bound complex, double-stranded DNA probes of length approximately 30 bp, termed here oligonucleotides 11 and 12, effectively competed for the formation of the complex (Tanaka, 2008).

These findings were important for two reasons. First, the observation that some oligonucleotides were capable of competition, whereas others were not, indicated that the interaction of the nuclear factor with the Act57B probe was sequence specific. Second, competition assays identified more precisely the region of the Act57B gene that was interacting with the nuclear factor (Tanaka, 2008).

Observation of the DNA sequence corresponding to the locations of oligonucleotides 11 and 12 revealed several repeats of a 5'-TATA-3' motif, which lies at the core of the recognition sequence of the transcription factor CF2 (Gorgos, 1992). Since CF2 is a C2H2 zinc finger protein that regulates gene expression in the chorion cells of the maturing egg in Drosophila (Gogos, 1992; Gogos, 1996), and since embryonic expression of CF2 is exclusive to the three muscle lineages of the mesoderm (Bagni, 2002), it was reasoned that CF2 might be interacting specifically with the Act57B enhancer (Tanaka, 2008).

To determine whether CF2 could interact with the Act57B gene enhancer, an electrophoretic mobility shift assay was carried out using as a probe the -390/-245 region and using the CF2 protein generated in vitro for binding. A robust interaction was found between CF2 and the -390/-245 region, and this interaction was competed for with excess nonradioactive -390/-245 sequence. More importantly, when the interaction of CF2 and -390/-245 probe was competed using the oligonucleotides spanning the region, CF2 binding was competed for only by oligonucleotides 11 and 12 (Tanaka, 2008).

These findings firstly demonstrated that CF2 is capable of interacting with the Act57B promoter. This is likely to be a relevant interaction given the broad expression of CF2 in the embryonic mesoderm. Second, these results showing identical responses to binding competition by a nuclear factor and by CF2 protein strongly suggested that CF2 is the interacting factor identified in nuclear extracts. It is noted that when CF2 protein is synthesized in vitro the electrophoretic mobility shift assays show two shifted bands of very similar mobilities. This probably arises from the synthesis of two CF2 isoforms in the in vitro expression system. Whether this arises from posttranslational modification of the CF2 protein or from internal translation initiation is not clear. Nevertheless, there is a strong and specific interaction between CF2 protein and the Act57B promoter region (Tanaka, 2008).

Clearly, the C2H2 zinc finger transcription factor CF2 is able to bind potently to regions of the Act57B promoter that were critical for full levels of gene expression, suggesting that it might be a positive regulator of Act57B transcription. To test the hypothesis that CF2 is an Act57B activator, a series of cell culture experiments was initiated aimed at determining whether MEF2 or CF2 can activate Act57B promoter-lacZ constructs. First, Drosophila S2 cells were cotransfected with the full-length -593/+2 promoter-lacZ, along with a MEF2 expression plasmid. This resulted in strong and reproducible activation of the reporter. In contrast, a point mutation of the putative MEF2-binding site within the -593/+2 promoter-lacZ construct dramatically impaired MEF2-dependent reporter responsiveness. These results confirmed the importance of the sole MEF2 site in this construct for Act57B gene activation (Tanaka, 2008). When the ability of CF2 to activate the wild-type Act57B-lacZ construct was tested, significant activation of the reporter occured, suggesting that CF2 was indeed an activator of this gene. To determine whether CF2 activates Act57B via the sites identified in vitro, the ability of CF2 to activate the 5'-deleted reporter constructs was tested. Indeed, deletion of 5' nucleotides to -390/+2, predicted to remove the most distal CF2 binding sites, reduced reporter activation by CF2 by ca. 50% compared to the full-length promoter fragment. The shortest version of the Act57B promoter, -278/+2, lacking both of the predicted CF2-binding regions, was completely unable to respond to CF2. Similarly, tests were performed to see whether the CF2-binding regions alone are sufficient for reporter activation, in the proximally truncated construct -593/-245. Here, there was strong CF2-dependent activation, although it did not reach full strength compared to the -593/+2 promoter construct. Apparently, some unknown regulatory elements in the proximal part of the Act57B promoter, perhaps its basal promoter, may additionally boost transcriptional activation initially conferred by the CF2-binding regions. Also, comparative analysis of this construct might be complicated by the observation that its basic activity was more than two times higher than that of the other tested constructs (Tanaka, 2008).

Taken together, these provide strong support for the identification of CF2 as an activator of Act57B: CF2 is capable of binding to two regions of the promoter, which were shown to be important for full reporter gene expression in vivo; furthermore, CF2 is identified as a strong transcriptional activator of the Act57B promoter via these same sequences in tissue culture (Tanaka, 2008).

Analyses performed on the promoter of Act57B provided direct evidence that CF2 can independently initiate and synergistically collaborate with MEF2 to maximize expression of this muscle-specific gene. However, it was of particular interest to investigate whether CF2 is more broadly involved in the regulation of the transcriptional activities of other structural muscle genes. In order to address this question, promoter reporters were analyzed of two genes for which the muscle enhancers had been identified: Troponin I (TnI) and Myosin heavy chain (Mhc) (Tanaka, 2008).

Transfection studies in cell culture indicated that CF2, as well as MEF2, could individually be effective transcriptional activators for both TnI and Mhc reporters. This is the first direct evidence in support of the roles of MEF2 and CF2 upon these structural genes. More importantly, it was found that CF2 and MEF2 also synergistically act upon the promoter-lacZ constructs for both TnI and Mhc. These findings supported a general role for the collaboration of CF2 and MEF2 in the control of embryonic muscle development in Drosophila. It was interesting that the titration analyses of the TnI and Mhc reporters showed different degrees of synergism between MEF2 and CF2: whereas dual activation of the TnI reporter with MEF2 and CF2 just slightly exceeded the predicted additive limit, the Mhc reporter showed a remarkable boost of activation conferred by the combination of these two factors (Tanaka, 2008).

Given the demonstrations that CF2 could activate Act57B gene expression in vivo and in tissue culture, it was shown that tests of loss of CF2 function resulted in a reduction or loss of expression of muscle structural genes. A Cf2 mutant named Df(2L)gamma, described by Bagni (2002), comprises a deletion of the Cf2 transcribed region and is homozygous larval lethal. In order to determine whether the loss of Cf2 function affects muscle structural gene expression, homozygous mutant embryos (at stage 16-17) or first-instar larvae were collected and assayed for the accumulation of the muscle-specific Act57B, TnI, and Mhc transcripts relative to the expression of the housekeeping Act5C cytoplasmic actin gene by using quantitative RT-PCR. As controls, heterozygous siblings were collected at embryonic or larval stages; these were assayed for expression of the same genes (Tanaka, 2008).

In embryos, there was an ~10% reduction in the levels of expression of all three muscle structural genes assayed relative to the Act5C control expression levels. While this change in expression is relatively small, it must be borne in mind that removal of the CF2 sites from the Act57B-lacZ reporter construct results in similarly moderate effects upon reporter gene expression, even though these two separate experiments cannot be directly compared. More strikingly, at the larval stage the reductions in the levels of muscle gene expression were much more severe, suggesting that a major function of CF2 might be to maintain high levels of expression in fully differentiated tissues. This reduction in the expression of the three genes tested is highly reproducible (Tanaka, 2008).

Overall, these studies identify CF2 as a potent activator of muscle gene expression both in vitro and in vivo and show that CF2 functions alongside MEF2 in controlling high levels of expression of muscle-specific genes (Tanaka, 2008).

This study has identified the first known collaborative factor for MEF2 function in Drosophila. CF2, a transcriptional regulator first identified as an activator of chorion protein genes in the female ovary, is expressed in all three muscle lineages in the embryonic mesoderm. The data indicate that CF2 interacts with the Act57B promoter both in the context of embryonic nuclear extracts and when expressed in vitro, and CF2 binding sites correspond precisely to the genomic regions required for full Act57B-lacZ activation. Furthermore, overexpression studies in vitro and in vivo establish a synergistic relationship between MEF2 and CF2 in the activation of Act57B. These studies define the first known embryonic function for this zinc finger transcriptional regulator. Nevertheless, it is also noted that even in the absence of CF2 sites, in the -270/+2 Act57B-lacZ construct there is significant muscle-specific expression. This indicates that CF2 contributes to high levels of structural gene expression but that it is not essential for the activation of Act57B (Tanaka, 2008).

Removing the genomic regions containing CF2 binding sites had clear effects upon Act57B-lacZ expression at stage 16. In contrast, removal of CF2 function from the embryos in the mutant analysis resulted in a more modest reduction in Act57B transcription. Although these two experiments utilize different approaches and different readouts, what might be the cause of this apparent discrepancy? The most reasonable explanation is that there are probably additional regulators of Act57B that bind to the genomic regions affected in the deletion analyses; thus, the deletions remove the influence not only of CF2 but also of other muscle-specific activators. In contrast, deletion of the CF2 gene might remove only the influence of CF2 from actin gene expression. Future deletion and point mutant analyses, carried out in the manner applied in this study, would test this hypothesis and could ultimately shed light upon the identity of such additional factors (Tanaka, 2008).

More broadly, MEF2 and CF2 can activate other muscle structural genes in Drosophila. Both of the enhancers that tested have predicted binding sites for MEF2 and CF2 proteins (TnI and Mhc); however, the current study privides the first direct functional tests of whether MEF2 and CF2 can transcriptionally activate these enhancers. The findings suggest strongly that the collaboration of MEF2 and CF2 during fly embryonic muscle development is a general and important phenomenon (Tanaka, 2008).

A simple tissue culture assay was used to demonstrate that MEF2 and CF2 collaborate to activate endogenous genes in the context of the intact genome, in addition to transiently transfected reporter constructs. The assay closely supports the findings from other experiments presented in this study and is somewhat more quantifiable than ectopic expression assays in embryos. This is because embryos already express significant levels of the targets genes in the mesoderm, whereas in vitro the baseline from nontransfected cells is essentially zero. Similarly, the lacZ reporter vectors that were use frequently show leaky promoter activity, which might ultimately result in an underestimation of the true activation of target promoter-lacZ constructs. In this sense, the activation of endogenous genes in S2 cells is highly informative (Tanaka, 2008).

Presumably, a more complete set of MEF2/CF2 targets could be generated by cotransfecting S2 cells with expression plasmids for CF2 and MEF2 and then performing an array analysis of transcripts upregulated after this treatment. Such a data set would significantly overlap with the analysis of mesoderm differentiation described by Sandmann (2006), although it might have the advantage of indicating which genes are direct targets of combinatorial activation by MEF2/CF2 (Tanaka, 2008).

Along these lines, the current studies also indicate that there are subtle, yet potentially important, differences between the responsiveness of different target genes to activation by MEF2 and CF2 alone. In tissue culture, Act57B is readily activated by MEF2 and CF2 individually, and yet TnI and Mhc induction are detected far less readily. This might be a simple result of different ease of detection for different targets. Alternatively, there might be a more mechanistic basis for these differences. One explanation might be related to the proximity of binding sites of the respective factors to the target promoter. For Act57B, both MEF2 and CF2 sites that were mapped are within 600 bp of the transcription start site. In contrast, for Mhc most of the candidate sites are located in the first intron, at least 800 bp away from the transcription start site. In contrast the other hand, putative binding sites for MEF2 and CF2 are in relatively close proximity to the TnI transcription start site. Thus, it is not clear whether binding site proximity plays a role in the activation of genes in vitro, although it should be noted that for TnI and Mhc many of the sites have yet to be validated by DNA-binding assays (Tanaka, 2008).

The data of Bagni (2002) indicate that Cf2 expression is dependent upon the function of the Mef2 gene in Drosophila embryos; these authors also show that MEF2 levels are unaffected in Cf2 mutants, at least at the embryonic stage. It is therefore most likely that the reduction in muscle structural gene transcripts in Cf2 mutants arises directly from a loss of CF2 protein rather than from indirect effects upon MEF2 levels. Clearly, one of the means by which MEF2 activates myogenesis at high levels is via the activation of its own collaborative factors. There is some precedent for this mechanism, both in muscle and other systems. In Drosophila cardiac development, the homeodomain transcription factor Tinman is a direct activator of the GATA factor pannier, after which Tin and Pnr can collaborate to activate structural genes such as Sulfonylurea receptor. The activation of, and then collaboration with, a cofactor appears to be a commonly used genomic regulatory mechanism (Tanaka, 2008).

CF2 activity and enhancer integration are required for proper muscle gene expression in Drosophila

The creation of the contractile apparatus in muscle involves the co-activation of a group of genes encoding muscle-specific proteins and the production of high levels of protein in a short period of time. The transcriptional control of six Drosophila muscle genes that have similar expression profiles were analyzed, and these mechanisms were compared with those employed to control the distinct expression profiles of other Drosophila genes. The regulatory elements controlling the transcription of co-expressed muscle genes share an Upstream Regulatory Element and an Intronic Regulatory Element. Moreover, similar clusters of MEF2 and CF2 binding sites are present in these elements. CF2 depletion alters the relative expression of thin and thick filament components. It is proposed that the appropriate rapid gene expression responses during muscle formation and the maintenance of each muscle type is guaranteed in Drosophila by equivalent duplicate enhancer-like elements. This mechanism may be exceptional and restricted to muscle genes, reflecting the specific requirement to mediate rapid muscle responses. However, it may also be a more general mechanism to control the correct levels of gene expression during development in each cell type (García-Zaragoza, 2008).

This study demonstrates that a large group of Drosophila muscle genes that present the same expression profile during development share a basic regulatory organization. This occurs both in genes encoding thick filament components namely, myosin heavy chain (Mhc), paramyosin (PM), tropomyosin 1 (Tm1) and tropomyosin 2 (Tm2), troponin T (TnT) and troponin I (TnI). genes encoding components of the thin filament. The elements involved are an Upstream Regulatory Element (URE) situated in the 5' upstream regions and an Intronic Regulatory Element (IRE) situated in introns 1 and 2 of each gene. Each of these regulatory elements, the URE and IRE, is sufficient to independently activate transcription in all muscle types and hence, they are inferred to be functionally equivalent. Moreover, these regulatory elements are mostly conserved among Drosophilidae. However, in each particular muscle, LacZ reporter activity varies depending on whether the URE or the IRE element is directing transgene expression. Thus, PM expression is very high in the IFM where the IRE element governs reporter expression, whereas it is low when directed by the URE element. In summary, either the URE or IRE elements independently govern transgene expression in all muscle types at all developmental stages. While the URE or IRE elements can dictate when and where these co-regulated genes are expressed during development, on their own they are unable to dictate the correct levels of protein expression in each muscle type (García-Zaragoza, 2008).

It has been demonstrated that the regulation of TnT transcription depends on the synergistic interaction between these two elements (Mas, 2004). Moreover, this synergism varies in each particular muscle type in order to produce the different specific levels of protein required. In conjunction with the data presented in this study and with that from similar studies performed on the TnI gene (Marin, 2004), it is concluded that the correct levels of expression of co-activated muscle genes are established in each muscle type through a direct or indirect interaction between the URE and IRE elements. Thus, this is considered to be a general mechanism that co-ordinates the expression of co-regulated muscle genes, establishing the proper levels of protein required by each muscle type and mediating the rapid responses required for muscle formation (Garcí-Zaragoza, 2008).

In mammals, duplicate enhancer-like elements capable of independently activating transcription in all muscle types and of directing the correct spatio-temporal expression of the same gene have yet to be identified. However, a number of modules or partial regulatory elements, located either upstream (USE/SURE) or downstream (IRE/FIRE) of the transcription initiation site confer transcriptional specificity to slow (TnIs) and fast (TnIf) genes in mouse muscle C2C12 cells. The importance of upstream and downstream elements in driving fibre specific expression of fast and slow TnI genes has been highlighted in studies of transgenic mice. As a result, additional unidentified enhancers were claimed to be necessary to recapitulate the quantitative endogenous expression of the TnI genes. In the context of the current data, further studies will be necessary to determine if, as in Drosophila, mammals use duplicate regulatory elements to establish the proper levels of gene expression in each muscle type. Indeed, preliminary data is available suggesting that these mechanisms might be totally or partially conserved (García-Zaragoza, 2008).

The basic regulatory design described in this study appears to differ in muscle genes with a more restricted expression profiles. This is the case for mPM, which is almost exclusively expressed in adults, as well as for actin 88F or flightin that are flight muscle-specific proteins. Recent functional studies to identify regulatory elements that control mPM expression indicated that the structure and organization of such regulatory elements is completely different to that identified in this study. The three elements identified in mPM are smaller and none of them contain conserved putative MEF2 or CF2 binding sites. The search for similar regulatory elements in actin 88F and flightin genes has been unsuccessful, possibly because these two genes are expressed in distinct muscle subsets than mPM (García-Zaragoza, 2008).

DNA microarray studies in Drosophila have offered an overview of genomic activity during development, grouping together thousands of genes with similar expression profiles. More recently this technology is being directed towards the understanding of the mechanisms driving simultaneous activation of each of these different groups of genes. The studies performed here on the structure of the different URE and IRE enhancer-like elements reveal that they share common organizational features. Thus, the systematic comparison of six Drosophila structural muscle genes and the large-genome scans identified clusters of MEF2-CF2 binding sites within 700-bp fragments. Moreover, these clusters were always located both upstream and downstream of the transcription initiation site of each of the genes analysed. Since these co-regulated genes share expression profiles, attention of this study was focused on other muscle genes that also share similar patterns of gene expression, such as actin 57B or actin 87E. Interestingly, similar clusters of MEF2 and CF2 binding sites were identified close to the transcription initiation sites of these two genes. In fact, it has been recently demonstrated that although both MEF2 and CF2 can individually activate actin gene expression, these two factors collaborate in regulating the actin 57B target gene in vitro and in vivo (Tanaka, 2008). However, no clusters were identified in transcriptional units with distinct developmental expression patterns, such as the mPM, actin 88F, flightin or TnC 41C genes, which are expressed almost exclusively in different subsets of the adult musculature. Furthermore, no MEF2-CF2 clusters were found in 'non-relevant' genes that are expressed in other organs or tissues, such as yellow-e2 that is expressed in the fly cuticle or proneural genes. These results demonstrate that the enhancer organization identified and the conserved clusters in whole-genome scans will be useful for guiding functional analyses. Indeed, this approach may serve to identify new functional components or members of co-expressed groups of genes, as well as grouping together genes with similar patterns of activity (García-Zaragoza, 2008).

A study was recently performed combining chromatin immunoprecipitation with microarray analysis to identify the in vivo 'occupied' MEF2 binding sites present in the whole Drosophila genome (Sandmann, 2006). 1015 overlapping genomic fragments were identified that were grouped as 670 independent DNA fragments, containing 1975 predicted MEF2 binding sites. In order to test the hypothesis that MEF2-CF2 clusters play an important role in the transcriptional regulation of a subset of muscle genes, MEF2/CF2 clusters were sought within these fragments. Significantly, it was found that 15.30% of the MEF2 binding sites have at least one CF2 binding site less than 200 bp away, a frequency that is 9 times higher than it would be expected for a random distribution. Hence, the location of CF2 sites in the vicinity of MEF2 binding sites appears to be conserved in this group of muscle enhancer-like elements. This conservation strongly suggests that these two transcription factors act together to fulfil a central role in regulating muscle development (García-Zaragoza, 2008).

It has been demonstrated that MEF2 is essential for muscle differentiation in both Drosophila and vertebrates, directly activating structural muscle genes. Recent studies demonstrated that MEF2 maintains its own expression in all differentiated muscle cell types, suggesting that it is required for muscle maintenance and growth during myogenesis. In vertebrate skeletal muscle, MEF2 cooperates with the myogenic basic helix-loop-helix (bHLH) transcription factors to activate and maintain the muscle phenotype. Indeed, in Drosophila Twist activates MEF2 expression and its expression declines during myogenesis. To date, no other factors are expressed in all muscles that might help maintain muscle-specific gene transcription and the muscle phenotype (García-Zaragoza, 2008).

Functional and computational analysis suggests that CF2 is a good candidate to collaborate with complexes containing MEF2 in maintaining muscle-specific gene transcription. Since no null CF2 mutants are available, a detailed study was conducted of two hypomorph CF2 mutants. Q-RT-PCR assays, flight tests and EM microscopy confirmed that depletion of the CF2 protein disturbs muscle gene expression, particularly the relative expression of thick and thin filament components. At distinct stages of development, a reduction in the expression of thin filament genes was mostly paralleled by an increase of thick filament gene transcription in both CF2 mutants. This imbalance was more pronounced as the flies aged. In summary, a strong reduction of CF2 alters the correct expression of thin and thick filament components through an unknown mechanism, affecting the stoichiometry of contractile proteins and consequently, myofibril assembly (García-Zaragoza, 2008).

It is concluded that CF2, together with MEF2 and other unknown factors, is an essential component of the macromolecular multi-protein complexes that bind to the URE and IRE enhancer-like elements. Supporting this hypothesis, a very weak interaction between MEF2 and CF2 proteins has been observed in GST-Pull Down assays. Within this complex MEF2 may maintain the muscle phenotype while CF2 guarantees the correct levels of expression of the genes encoding the protein components of thin and thick filaments (García-Zaragoza, 2008).

This study has demonstrated the presence of functionally similar enhancer-like duplicates in Drosophila muscle genes. Direct or indirect interactions between these elements guarantee rapid and strong responses of structural muscle gene expression in muscle formation within each muscle type. It is proposed that this mechanism, or a similar one, might be a general mechanism to control the correct levels of gene expression during development of functionally related co-expressed genes in all cell types (García-Zaragoza, 2008).

The Drosophila zinc finger transcription factor CF2 is a myogenic marker downstream of MEF2 during muscle development

The Drosophila C2-H2-type zinc-finger transcription factor CF2 has been shown to regulate follicular cell fate determination during oogenesis. CF2 is also expressed in the developing muscles of the embryo where it first appears at stage 12 at the time of skeletal myoblast fusion. Later it is expressed in all muscle lineages including skeletal, visceral and cardiac. Epistatic analysis has shown that CF2 expression is dependent on the myogenic factor MEF2 (Bagni, 2002).

The Drosophila CF2 zinc finger protein was first identified through its role in dorsoventral pattern formation during oogenesis. CF2 mRNA is expressed during embryogenesis. This study reports on the tissue-specific expression of CF2 protein in the Drosophila embryo. No appreciable levels of CF2 protein are detected at early embryonic stages up to stage 11, that is about 7 h after egg laying at 25°C (AEL). Low-level CF2 expression is first detected at early to mid-stage 12 (8-9 h AEL) in visceral and somatic mesoderm, immediately following germband retraction. This temporal pattern coincides with or immediately follows the onset of myoblast fusion (7.5-8 h AEL). At stage 13 (ca. 9-10 h AEL), CF2 expression in skeletal muscle cells become clearly discernible with increased nuclear localization. At later stages, CF2 is distinctively localized in the nuclei of all skeletal muscles. The pattern of staining in these embryos reflects the evolving pattern of somatic muscles (Bagni, 2002).

The expression of CF2 in visceral muscles was examined at a higher resolution. At stage 13, CF2 is expressed in a strip of visceral mesodermal cells on either side of the embryo. These two strips of cells provide a substrate for the elongating anterior and posterior midgut as well as a reservoir of visceral muscle cells that will form the midgut lining. At stages 14 and 15, CF2 expression is detected in the lining of midgut as well as in the foregut. Also, strips of CF2-expressing cells are observed along the surface of the midgut. They might potentially serve as a reservoir for lining the expanding midgut surface. Unlike that in skeletal muscles, CF2 expression in the gut lining fades after stage 16 (Bagni, 2002).

In the cardiac tissue, CF2 is also expressed at later stages. No CF2 expression is detected in the cardioblasts before stage 13, although cardiac precursor cells are already specified before germband retraction at stage 11. Strong cardiac expression of CF2 appears at stage 14 and persists during the formation and completion of the heart tube. There is no CF2 expression in the pericardiac cells (Bagni, 2002).

The expression of CF2 in skeletal, visceral and cardiac muscle cells resembles that of the D-MEF2 protein, although the onset of D-MEF2 expression is much earlier. This suggests that CF2 expression could be dependent on the earlier activity of D-MEF2. Indeed, CF2 protein is not detectable at stage 11 (6-7 h AEL), when D-MEF2 is present in both somatic and visceral mesoderm. At later stages, the two proteins show the same expression pattern in visceral, skeletal and cardiac muscle nuclei. In the protein-null D-mef222-21 mutant that prevents the formation of all muscles (although not of muscle precursors), CF2 expression is abolished in all muscle lineages. Conversely, Df(2L)γ27, which deletes the CF2 coding region and approximately 20 kb of DNA upstream of the CF2 gene, has no effect on D-mef2 expression. These results establish the fact that D-meF2 expression occurs independent of CF2 and demonstrate that the CF2 transcription factor is downstream of D-meF2 in the hierarchy of myogenic transcription factors (Bagni, 2002).

Myogenesis in Drosophila and in vertebrates is a multistep process. One of the key regulatory genes in both insect and vertebrate muscle development is the MADS-box gene mef2. However, only a few myogenic regulators downstream of D-mef2 have been identified, including muscleblind and lame duck. In addition, one novel D-mef2 downstream gene has been verified from a direct comparison of gene expression patterns between wild-type and D-mef2 mutants. It is worth noting that the recent microarray analysis of myogenic gene expression did not encompass all known Drosophila genes such as CF2. This demonstration of CF2 expression in skeletal, visceral and cardiac muscles and its potential role as a downstream regulator of D-mef2 should help expand future studies on the myogenic processes (Bagni, 2002).

The transcriptional factor CF2 is a mediator of EGF-R-activated dorsoventral patterning in Drosophila oogenesis

Establishment of dorsoventral polarity during Drosophila oogenesis requires localized intercellular communication between the follicular cells and the oocyte. This is initiated by the transmission of a 'dorsal signal' from the oocyte to the anterior dorsal follicle cells by the EGF receptor (EGF-R) pathway and is followed by transmission of a second signal from the ventral follicle cells back to the embryo. The zinc finger transcription factor CF2 participates in these processes. CF2 is suppressed by EGF-R signaling in the anterior dorsal follicle cells. Altered expression patterns of CF2 result in specific dorsoventral patterning defects in egg chambers and in embryos, as demonstrated phenotypically and with molecular markers. CF2 appears to act as a repressor of dorsal follicle cell fates and specifically as a repressor of the rhomboid gene transcription (Hsu, 1996; full text of article).

Down-regulation of transcription factor CF2 by Drosophila Ras/MAP kinase signaling in oogenesis: cytoplasmic retention and degradation.

Dorsoventral (D/V) patterning in Drosophila oogenesis is initiated by the transmission of a TGF-alpha-like ligand, Gurken (Grk), from the oocyte to the anterodorsal follicle cells, activating the EGF receptor (Egfr) signaling pathway. The zinc-finger transcription factor CF2 is a negative regulator of the rhomboid (rho) gene that encodes an essential membrane-bound component of the dorsalizing pathway. Expression of CF2 itself is negatively regulated by the activated Egfr. CF2 is the target of down-regulation by the MAPK kinase cascade, and this down-regulation is independent of the Rho function. These results suggest that D/V patterning involves a two-step signaling process: the initial Egfr signal, which represses CF2 and induces rho expression; and the subsequent Egfr + Rho signal, which determines the dorsal cell fates. Furthermore, this study shows that CF2 down-regulation occurs at the post-translational level through a mechanism involving coupled cytoplasmic retention and degradation (Mantrova, 1998; full text of article).

Multiple zinc finger forms resulting from developmentally regulated alternative splicing of a transcription factor gene

Transcripts encoding CF2 are subject to developmentally regulated alternative splicing, and they encode protein isoforms that differ in the number of zinc fingers. One testis-specific RNA encodes an isoform that includes three zinc fingers and a frame-shifted segment. Two other transcripts encode isoforms with six and seven zinc fingers which bind to distinct promoters and DNA target sequences. Thus, because of alternative splicing, a single gene appears to encode distinct DNA-binding proteins, each capable of regulating different gene sets in different tissues and developmental periods (Hsu, 1992; full text of article).

Sequence discrimination by alternatively spliced isoforms of a DNA binding zinc finger domain

Two major developmentally regulated isoforms of the Drosophila chorion transcription factor CF2 differ by an extra zinc finger within the DNA binding domain. The preferred DNA binding sites were determined and are distinguished by an internal duplication of TAT in the site recognized by the isoform with the extra finger. The results are consistent with modular interactions between zinc fingers and trinucleotides and also suggest rules for recognition of AT-rich DNA sites by zinc finger proteins. The results show how modular finger interactions with trinucleotides can be used, in conjunction with alternative splicing, to alter the binding specificity and increase the spectrum of sites recognized by a DNA binding domain. Thus, CF2 may potentially regulate distinct sets of target genes during development (Gogos, 1992; full text of article).

Recognition of diverse sequences by class I zinc fingers: asymmetries and indirect effects on specificity in the interaction between CF2II and A+T-rich elements

The Drosophila CF2II protein, which contains zinc fingers of the Cys2His2 type and recognizes an A+T-rich sequence, behaves in cell culture as an activator of a reporter chloramphenicol acetyltransferase gene. This activity depends on C-terminal but not N-terminal zinc fingers, as does in vitro DNA binding. By site-specific mutagenesis and binding site selection, the critical amino acid-base interactions were identified. Mutations of single amino acid residues at the leading edge of the recognition helix are rarely neutral: many result in a slight change in affinity for the ideal DNA target site; some cause major loss of affinity; and others change specificity for as many as two bases in the target site. Compared to zinc fingers that recognize G+C-rich DNA, CF2II fingers appear to bind to A+T-rich DNA in a generally similar manner, but with additional flexibility and amino acid-base interactions. The results illustrate how zinc fingers may be evolving to recognize an unusually diverse set of DNA sequences (Gogos, 1996; full text of article).


Search PubMed for articles about Drosophila CF2

Bagni, C., Bray, S., Gogos, J. A., Kafatos, F. C. and Hsu, T. (2002). The Drosophila zinc finger transcription factor CF2 is a myogenic marker downstream of MEF2 during muscle development. Mech. Dev. 117: 265-268. PubMed ID: 12204268

GarcĂ­a-Zaragoza, E., et al. (2008). CF2 activity and enhancer integration are required for proper muscle gene expression in Drosophila. Mech. Dev. 125: 617-630. PubMed ID: 18448314

Gogos, J. A., Hsu, T., Bolton, J. and Kafatos. F. C. (1992). Sequence discrimination by alternatively spliced isoforms of a DNA binding zinc finger domain. Science 257: 1951-1955. PubMed ID: 1290524

Gogos, J. A., et al. (1996). Recognition of diverse sequences by class I zinc fingers: asymmetries and indirect effects on specificity in the interaction between CF2II and A+T-rich elements. Proc. Natl. Acad. Sci. 93: 2159-2164. PubMed ID: 8700901

Hsu, T., Gogos, J. A., Kirsh, S. A. and Kafatos, F. C. (1992). Multiple zinc finger forms resulting from developmentally regulated alternative splicing of a transcription factor gene. Science 257(5078): 1946-50. PubMed ID: 1411512

Hsu, T., Bagni, C., Sutherland, J. D. and Kafatos, F. C. (1996). The transcriptional factor CF2 is a mediator of EGF-R-activated dorsoventral patterning in Drosophila oogenesis. Genes Dev. 10(11): 1411-21. PubMed ID: 8647437

Kelly, K. K., Meadows, S. M. and Cripps, R. M. (2002). Drosophila MEF2 is a direct regulator of Actin57B transcription in cardiac, skeletal, and visceral muscle lineages. Mech. Dev. 110: 39-50. PubMed ID: 11744367

Mantrova, E. Y. and Hsu, T. (1998). Down-regulation of transcription factor CF2 by Drosophila Ras/MAP kinase signaling in oogenesis: cytoplasmic retention and degradation. Genes Dev. 12(8): 1166-75. PubMed ID: 9553046

Marin, M. C., Rodriguez, J. R. and Ferrus, A. (2004). Transcription of Drosophila troponin I gene is regulated by two conserved, functionally identical, synergistic elements. Mol. Biol. Cell 15: 1185-1196. PubMed ID: 14718563

Mas, J. A., Garcia-Zaragoza, E. and Cervera, M. (2004). Two functionally identical modular enhancers in Drosophila troponin T gene establish the correct protein levels in different muscle types. Mol. Biol. Cell 15: 1931-1945. PubMed ID: 14718560

Sandmann, T., et al. (2006). A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. Dev. Cell 10: 797-807. PubMed ID: 16740481

Tanaka, K. K., Bryantsev, A. L. and Cripps, R. M. (2008). Myocyte enhancer factor 2 and chorion factor 2 collaborate in activation of the myogenic program in Drosophila. Mol. Cell Biol. 28: 1616-1629. PubMed ID: 18160709

Biological Overview

date revised: 1 September 2008

Home page: The Interactive Fly © 2008 Thomas Brody, Ph.D.

The Interactive Fly resides on the
Society for Developmental Biology's Web server.